gefitinib has been researched along with Virus Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Ballon-Landa, E; Galen, B; Kalinowski, A; Knoff, D; Koff, JL; Lanier, LL; Min-Oo, G; Nadel, JA; Ueki, I | 1 |
1 review(s) available for gefitinib and Virus Diseases
| Article | Year |
|---|---|
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
2 other study(ies) available for gefitinib and Virus Diseases
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
EGFR activation suppresses respiratory virus-induced IRF1-dependent CXCL10 production.
Topics: Bronchi; Cell Line; Cell Movement; Chemokine CXCL10; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Humans; Influenza A Virus, H1N1 Subtype; Interferon Regulatory Factor-1; Interleukin-8; Killer Cells, Natural; Quinazolines; Respiratory Syncytial Viruses; Rhinovirus; Signal Transduction; Virus Diseases | 2014 |